Analyst Price Target is $60.75
▲ +30.36% Upside Potential
This price target is based on 8 analysts offering 12 month price targets for Avidity Biosciences in the last 3 months. The average price target is $60.75, with a high forecast of $96.00 and a low forecast of $45.00. The average price target represents a 30.36% upside from the last price of $46.60.
Current Consensus is
Buy
The current consensus among 8 polled investment analysts is to buy stock in Avidity Biosciences. This Buy consensus rating has held steady for over two years.
Avidity Biosciences, Inc., a biopharmaceutical company, engages in the delivery of RNA therapeutics. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat diseases previously untreatable with RNA therapeutics. The company's lead product candidate AOC 1001 for the treatment of myotonic dystrophy type 1, a rare monogenic muscle disease that is in phase 1/2 clinical trial. Its other products in pipeline include AOC 1044 for the treatment of duchenne muscular dystrophy, which is under phase 1/2 clinical development trial; and AOC 1020 to treat facioscapulohumeral muscular dystrophy that is in phase 1/2 clinical trial. The company is developing products for rare skeletal muscle and rare cardiac diseases. Avidity Biosciences, Inc. was incorporated in 2012 and is headquartered in San Diego, California.
Read More